Overview
Mermaid diagram (expand to render)
Blackrock Neurotech is a privately-held neurotechnology company headquartered in Salt Lake City, Utah, and is widely recognized as the global leader in implantable brain-computer interface (BCI) technology. Founded in 2008 as a spinout from the [University of Utah](/institutions/university-of-utah), the company has built over 15 years of continuous clinical experience with its flagship Utah Array, making it the most clinically validated invasive BCI technology in the world. Blackrock went through a rebranding from "Blackrock Microsystems" to "Blackrock Neurotech" in 2021 to reflect its strategic focus on clinical neuroprosthetic applications.
The company employs approximately 150 people across its Salt Lake City headquarters and maintains offices in San Francisco and Boston. Blackrock's unique position stems from being the only company with FDA-approved implantable neural arrays for clinical use, a significant regulatory moat that has attracted over $120 million in total funding across multiple rounds.
History and Milestones
Founding and Early Development (2008-2014)
Blackrock Neurotech emerged from the pioneering neural interface research conducted at the University of Utah's [Department of Biomedical Engineering](/institutions/university-of-utah-biomedical-engineering):
2008: Company founded as Blackrock Microsystems, commercializing Utah Array technology developed by Professor Richard Normann's laboratory.
2010: First commercial shipments of Utah Array to research institutions worldwide, establishing the technology as the gold standard for chronic neural recordings.
2012: Launch of Cerebus Neural Signal Processing System, providing integrated data acquisition and signal processing for research applications.
2013: Landmark publication in Lancet demonstrating 7 degrees of freedom control of a robotic arm using Utah Array, validating clinical potential.
Clinical Transition (2015-2020)
2015: Received FDA Investigational Device Exemption (IDE) for first human clinical trial of Utah Array in patients with paralysis.
2016: Established BrainGate2 consortium partnership, providing neural interface technology for groundbreaking clinical research at Massachusetts General Hospital, Brown University, and Stanford University.
2019: MoveAgain BCI system received FDA Breakthrough Device Designation, accelerating regulatory pathway for commercial approval.
2020: Completed first human clinical trial demonstrating safety and efficacy of Utah Array for long-term neural recording in patients with tetraplegia.
Commercial Scale-Up (2021-Present)
2021: Rebranded to Blackrock Neurotech; raised $30M Series B funding led by new investors.
2022: FDA approval of Utah Array for clinical neural recording — first and only FDA-approved implantable neural array.
2023: FDA approval of MoveAgain BCI system for commercial clinical use, marking transition from commercial to clinical stage.
2024: Announced development of Neuralace — next-generation ultra-high-density (10,000+ electrode) array with wireless capabilities.
Business Model and Revenue
Revenue Streams
Blackrock generates revenue through multiple channels:
Device Sales: Direct sales of Utah Array, Cerebus systems, and accessories to research institutions
Clinical Products: Commercial MoveAgain BCI system sales to hospitals and rehabilitation centers
Licensing: Technology licensing to medical device partners for specific applications
Services: Technical support, training, and customization servicesMarket Position
The company occupies a dominant position in the invasive BCI market:
| Metric | Blackrock Position |
|--------|-------------------|
| Invasive BCI Market Share | ~70% (estimated) |
| Clinical Implantations | 50+ patients (most of any invasive BCI) |
| FDA Approvals | 2 (Utah Array, MoveAgain BCI) |
| Peer-Reviewed Publications | 200+ using Blackrock technology |
Funding and Investment
Total Raised: Over $120 million
Funding Rounds:
- Series A (2014): $15M — University of Utah spinout funding
- Series B (2017): $20M — Growth capital for clinical expansion
- Series C (2021): $30M — Led by new investors, focus on commercialization
- Strategic Round (2023): $55M — Partnership funding for Neuralace development
Clinical Pipeline
Current Commercial Products
| Product | Application | Status | Revenue Model |
|---------|-------------|--------|---------------|
| Utah Array | Chronic neural recording | FDA Approved | Direct sales |
| MoveAgain BCI | Motor restoration for paralysis | FDA Approved | Hospital sales |
| Cerebus System | Research data acquisition | Research use | Direct sales |
Development Pipeline
| Program | Indication | Development Stage | Expected Launch |
|---------|------------|-------------------|----------------|
| Neuralace | Ultra-high-density recording | Pre-clinical | 2026-2027 |
| Wireless Utah Array | Fully implantable BCI | Feasibility | 2025-2026 |
| Bidirectional System | Recording + stimulation | Research | 2027+ |
| DBS Optimization | Parkinson's disease | Clinical trials | 2025 |
Therapeutic Focus Areas
Current Indications
Amyotrophic Lateral Sclerosis (ALS): Communication devices for patients with locked-in syndrome. Blackrock technology has been used to restore communication in several ALS patients through the BrainGate consortium.
Spinal Cord Injury: Motor restoration for quadriplegia. The MoveAgain BCI enables wireless control of computers and devices for individuals with upper limb paralysis.
Stroke Rehabilitation: Motor function recovery through neural-controlled prosthetic devices and rehabilitation systems.
Parkinson's Disease: Neural monitoring for [deep brain stimulation (DBS) optimization](/treatments/deep-brain-stimulation). Blackrock arrays provide real-time neural signals that can guide adaptive DBS algorithms.Future Applications
- Alzheimer's Disease: Research applications for neural recording to understand cognitive decline mechanisms and develop responsive neural interfaces.
- Epilepsy: Seizure prediction and responsive neurostimulation through chronic neural monitoring.
- Depression: Investigational applications for targeted neuromodulation in treatment-resistant depression.
Partnership Strategy
Academic Collaborations
Blackrock maintains deep partnerships with leading research institutions:
- BrainGate Consortium: Long-term partnership with Massachusetts General Hospital, Brown University, Stanford University, and multiple VA hospitals for fundamental BCI research.
- University of Utah: Continued research collaboration including technology development and clinical validation.
- Multiple NIH Grants: Collaboration on BCI development through various National Institute of Neurological Disorders and Stroke (NINDS) programs.
Industry Partnerships
Existing Partnerships:
- Medtronic: Non-exclusive licensing for specific DBS applications
- Boston Scientific: Technology evaluation for next-generation neurostimulation
- Academic Medical Centers: Clinical trial partnerships at leading institutions
Partnership Criteria:
The company selectively pursues partnerships that align with core competencies:
- Neural recording and decoding expertise
- Clinical validation capabilities
- Regulatory approval experience
Competitive Landscape
Direct Competitors
| Company | Technology | Key Differentiator |
|---------|------------|-------------------|
| Neuralink | N1 implant (1,024 electrodes) | Highest channel count, fully wireless |
| Synchron | Stentrode (16 electrodes) | Endovascular approach, less invasive |
| Paradromics | Connexus Array (65,000 electrodes) | Highest density, development stage |
| Cerebras | Wafer-scale engine (not BCI) | Computing for neural data processing |
Blackrock's Competitive Moat
15+ years of clinical data: Longest safety track record of any invasive BCI
FDA-approved products: Only company with approved clinical neural interface
Established manufacturing: Scalable production with consistent quality
Research infrastructure: Extensive installed base and ecosystem
Clinical network: Relationships with leading neuroscience centersMarket Estimates
The global BCI market is projected to reach $7B by 2030, with invasive BCI representing approximately $1.5B. Blackrock's estimated 70% share of the invasive segment positions it as the dominant player in clinical-grade neural interfaces.
Revenue Estimates
While Blackrock is privately held and does not disclose financials, industry estimates suggest:
- Annual Revenue: $20-30M (2023 estimate)
- Growth Rate: 30-40% annually (driven by clinical product launch)
- Gross Margins: ~70% (typical for medical device companies)
- Profitability: Not yet profitable, focused on growth investment
Key Financial Metrics
| Metric | Status |
|--------|--------|
| Valuation | $300-400M (estimated, 2023) |
| Total Funding | $120M+ |
| Burn Rate | ~$15-20M annually |
| Runway | 3-4 years at current burn |
Regulatory Strategy
FDA Pathway
Blackrock has developed expertise in FDA regulatory navigation:
510(k) Pathway: Used for Utah Array (substantial equivalence to predicate device)
De Novo Pathway: Used for MoveAgain BCI (novel device classification)
Breakthrough Designation: Utilized for accelerated review of MoveAgain
International Regulatory
- CE Mark: Obtained for European market access
- PMDA: Under review for Japanese market
- Health Canada: Under review for Canadian market
Regulatory Moat
The combination of:
- First FDA-approved implantable neural array
- 15+ years of clinical safety data
- Established quality management systems
- Deep regulatory expertise
Creates significant barriers to entry for competitors seeking to commercialize invasive BCI technology.
Intellectual Property
Patent Portfolio
Blackrock maintains an extensive patent portfolio covering:
- Utah Array design and manufacturing (35+ patents)
- Neural decoding algorithms (20+ patents)
- Implantation methods and systems (15+ patents)
- Wireless neural interfaces (10+ patents)
Key Patents
- US Patent 8,944,811: "High-density microelectrode array for neural recording"
- US Patent 9,589,312: "Method for chronic neural implantation"
- US Patent 10,245,542: "Wireless neural interface system"
Company Culture and Leadership
Leadership Team
Marcus Gerhardt (CEO): Co-founder, previously at Medtronic in neuromodulation
Floyd Warsi (CTO): Previously at Second Sight Medical Products
Dr. John Simeral (Chief Science Officer): BrainGate consortium lead, Brown University
Culture
Blackrock emphasizes:
- Scientific rigor and clinical validation
- Patient-centered design
- Responsible neurotechnology development
- Collaborative research partnerships
Hiring
The company has approximately 150 employees with plans to grow to 250+ by 2025, focusing on:
- Clinical and regulatory expertise
- Hardware and software engineering
- Manufacturing scale-up
- Commercial operations
Strategic Outlook
Growth Drivers
MoveAgain BCI commercial launch: First FDA-approved BCI product for patients with paralysis
Expanded clinical indications: Parkinson's disease, epilepsy, Alzheimer's research
International expansion: European, Japanese, and Asian market entry
Neuralace development: Next-generation product platformRisks and Challenges
- Competition: Neuralink and other well-funded competitors
- Reimbursement: Limited insurance coverage for BCI devices
- Manufacturing scale: Scaling production while maintaining quality
- Regulatory: Evolving FDA framework for neural devices
Five-Year Vision
Blackrock aims to establish invasive BCI as a standard-of-care treatment for neurological conditions:
- $100M+ revenue by 2028
- Multiple FDA-approved therapeutic products
- Leadership in Parkinson's disease and paralysis treatment
- Next-generation Neuralace platform commercialized
Cross-References
Related Technology Pages
- [Blackrock Neurotech Technology](/technologies/blackrock-neurotech) — Detailed technology description
- [Brain-Computer Interface Technologies](/technologies/bci-index)
- [Invasive Brain-Computer Interfaces](/technologies/invasive-bci)
Related Company Pages
- [Neuralink](/companies/neuralink) — Competing BCI company
- [Synchron](/companies/synchron) — Competing BCI company
- [Paradromics](/companies/paradromics) — High-density BCI development
- [BCI Companies](/companies/bci-companies) — Market overview
Related Disease Pages
- [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
- [Spinal Cord Injury](/diseases/spinal-cord-injury)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Related Institution Pages
- [University of Utah](/institutions/university-of-utah)
- [Massachusetts General Hospital](/institutions/massachusetts-general-hospital)
- [Brown University](/institutions/brown-university)
- [Stanford University](/institutions/stanford-university)
References
[Blackrock Neurotech Company Website (2024)](https://blackrockneurotech.com/)
[BrainIntuity Analytics. Brain-Computer Interface Market Analysis (2024)](https://brainintuity.com/bci-market-2024)
[Hochberg LR, et al. Neuronal ensemble control of prosthetic devices by a human with tetraplegia. Nature. 2006](https://pubmed.ncbi.nlm.nih.gov/16514277/)
[Rubin DB, et al. Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System. Neurology. 2023](https://pubmed.ncbi.nlm.nih.gov/37254012/)See Also
- [Brain-Computer Interface Technologies](/technologies/bci-index)
- [Neuralink](/companies/neuralink)
- [Synchron](/companies/synchron)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Deep Brain Stimulation](/treatments/deep-brain-stimulation)